ConductScience.org, home

Paper42636799

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.

Wang S and 35 others. Cell Rep Med, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma. Papers, record 42636799. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42636799

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.
PubMed
Journal
Cell Rep Med
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-22
PubMed

Authors36

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang SSteven
2Mapar PParisa
3Moldovan NNorbert
4van der Pol YYmke
5Safrastyan AAram
6van Werkhoven EErik
7Tantyo NANormastuti Adhini
8Snieder BBart
9Do Brito Valente AFAndré F
10de Jonge AVA Vera
11Dinmohamed AAvinash
12Drees EEEEsther E E
13Roemer MGMMargaretha G M
14Ylstra BBauke
15Klerk CPWClara P W
16Strobbe LLeonie
17Sandberg YYorick
18Boersma RSRinske S
19Koene HHarry
20Pruijt HHans

Source PubMed

See all 36 authorsDownload CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lymphoma, Large B-Cell, DiffuseMajor topic
Cell-Free Nucleic AcidsMajor topic
GenomicsMajor topic
Humans
Prognosis
Female
Male
Middle Aged
Aged
Whole Genome Sequencing
Biomarkers, Tumor

Source PubMed

Download CSV of topics

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140833414Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/40833414PubMed
234932792Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.Blood2022https://conductscience.org/library/papers/34932792PubMed
333122345Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.Clin Cancer Res2021https://conductscience.org/library/papers/33122345PubMed
420435884Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.Blood2010https://conductscience.org/library/papers/20435884PubMed
541428995Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.J Clin Oncol2026https://conductscience.org/library/papers/41428995PubMed
630125215Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.J Clin Oncol2018https://conductscience.org/library/papers/30125215PubMed
728774879Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood2017https://conductscience.org/library/papers/28774879PubMed
828668386
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Lancet Oncol2017https://conductscience.org/library/papers/28668386PubMed
929713087Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med2018https://conductscience.org/library/papers/29713087PubMed
1032554709ctDNA monitoring using patient-specific sequencing and integration of variant reads.Sci Transl Med2020https://conductscience.org/library/papers/32554709PubMed
1135732829The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia2022https://conductscience.org/library/papers/35732829PubMed
1234050156Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden.Nat Commun2021https://conductscience.org/library/papers/34050156PubMed
1337001036Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.Blood2023https://conductscience.org/library/papers/37001036PubMed
1440055810Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40055810PubMed
1542215793Advancing the applications of liquid biopsies in oncology.Nat Rev Genet2026https://conductscience.org/library/papers/42215793PubMed
1623859481Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome.Eur J Haematol2013https://conductscience.org/library/papers/23859481PubMed
1729109393Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.Nat Commun2017https://conductscience.org/library/papers/29109393PubMed
1820080505Fast and accurate long-read alignment with Burrows-Wheeler transform.Bioinformatics2010https://conductscience.org/library/papers/20080505PubMed
1939089812International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.J Nucl Med2024https://conductscience.org/library/papers/39089812PubMed
2020212248Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.J Clin Oncol2010https://conductscience.org/library/papers/20212248PubMed

See all 59 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42887064Cell-free DNA fragmentomics and epigenomic profiling in hematologic malignancies: current evidence, translational limitations, and future directions.Transl Oncol2026https://conductscience.org/library/papers/42887064

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42636799

GET https://conductscience.org/api/papers/v1/42636799/authors?page=2